Bavarian Nordic A/S
CSE:BAVA
Bavarian Nordic A/S
Cost of Revenue
Bavarian Nordic A/S
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cost of Revenue
-kr2.9B
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
-19%
|
|
|
Genmab A/S
CSE:GMAB
|
Cost of Revenue
-kr985m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cost of Revenue
-kr7.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-80%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cost of Revenue
-€44.3m
|
CAGR 3-Years
-133%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cost of Revenue
-kr11.7m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-8%
|
|
|
Saniona AB
STO:SANION
|
Cost of Revenue
-kr50.1m
|
CAGR 3-Years
41%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-12%
|
|
Bavarian Nordic A/S
Glance View
Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.
See Also
What is Bavarian Nordic A/S's Cost of Revenue?
Cost of Revenue
-2.9B
DKK
Based on the financial report for Dec 31, 2024, Bavarian Nordic A/S's Cost of Revenue amounts to -2.9B DKK.
What is Bavarian Nordic A/S's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-19%
Over the last year, the Cost of Revenue growth was -18%. The average annual Cost of Revenue growth rates for Bavarian Nordic A/S have been -30% over the past three years , -52% over the past five years , and -19% over the past ten years .
You don't have any saved screeners yet